Українська Русский English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2018; 64(3): 79-90

THE ROLE OF MATRIX METALLOPROTEINASES AND POLYMORPHISMS OF THEIR GENES IN THE DEVELOPMENT OF CORONARY HEART DISEASE

O. Pogorielova, V. Garbuzova, L. Prystupa, A. Fadeeva

    Sumy State University, Sumy, Ukraine
DOI: https://doi.org/10.15407/fz64.03.079

Abstract

The aim of our work was the systematization of information on the role of MMP-3, -8, -9 in the pathogenesis of atherosclerosis, atherosclerotic plaque destabilization and analysis of currently available sources (PubMed, ScienceDirect) on the association of polymorphisms (5A/6A, C-799→Т, С-1562→Т) with the development of chronic coronary artery disease (CAD) and acute coronary syndrome (ACS) in representatives of different populations. The results of our studies revealed the association of the T-allel C-1562→T-polymorphism of MMP-9 gene with development and progression of atherosclerosis in Chinese, Iranian, French, British, and Indonesian populations. The literature data confirmed the association of the 5A/5A-genotype of the 5A/6A-polymorphism of MMP-3 gene with the severity and volume of atherosclerotic lesion of the coronary arteries in Japanese population, the coronary artery calcification in older male Finns, and the association of 6A/5A and 5A/5A-genotypes with development of carotid atherosclerosis and stable forms of IHD in representatives of Russian and Turkish populations. The association of C-799→T of MMP-8 polymorphism with the development of IHD in representatives of the Finnish and Chinese populations was proved. The actuality, necessity and perspective of the study as a genetic component of IHD development in representatives of Ukrainian population are shown.

Keywords: coronary artery disease; acute coronary syndrome; matrix metalloproteinases; gene polymorphism

Full text: (PDF, in Ukrainian)

References

  1. Allender S, Scarborough P, Peto V, Rayner M. British Heart Foundation Health Promotion Research Group, Department of Public Health, University of Oxford; Leal J., Luengo-Fernandez R., Gray A.; Health Economic Research Group, Department of Public Health, University of Oxford. European cardiovascular disease statistics 2008. http://www.heartstats.org.
    2.  
  2. Akasaka T, Kubo T, Mizukoshi M. Pathophysiology of acute coronary syndrome assessed by optical coherence tomography. J Cardiol. 2010;56(1):8-14. CrossRef PubMed
    3.  
  3. Aldons J. Lusis Atherosclerosis. Nature. 2000; 407:233-41. CrossRef PubMed PubMedCentral
    4.  
  4. Ataman OV. Pathological Physiology. V. 2. Pathophysiology of organs and systems. Kyiv: Naukova Dumka: 2016.167-78. [Ukrainian].
    5.  
  5. Vacek TP, Rehman S, Neamtu D. et al. Matrix metalloproteinases in atherosclerosis: role of nitric oxide, hydrogen sulfide, homocysteine, and polymorphisms. Vasc Health Risk Manag. 2015;11:173-83. CrossRef PubMed PubMedCentral
    6.  
  6. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis. The good, the bad, and the ugly. Circ Res. 2002;90:251-62. PubMed
    7.  
  7. Dollery CM, Libby P. Atherosclerosis and proteinase activation. Cardiovasc Res. 2006;69(3):625-35. CrossRef PubMed
    8.  
  8. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circulation Res. 2003;2: 827-39. CrossRef PubMed
    9.  
  9. Turna AA, Toguzova RT. MMPs and cardio-vascular diseases. Arter Hyperten. 2009;15(5):532-38. [Russian].
    10.  
  10. Sbardella D, Fasciglione GF, Gioia M. et al. Human matrix metalloproteinases: An ubiquitarian class of enzymes involved in several pathological processes. Mol Aspects Med. 2012;33:119-208. CrossRef PubMed
    11.  
  11. Markelova EV, Zdor VV, Romanchuk AL, Byrko ON. 2016. MMPs and their relation with cytokine system - diagnostic and prognostic potential. Imm Alleg Infect. 2016;(2):11-22. [ Russian].
    12.  
  12. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell. Dev. Biol. 2001;17:463-516. CrossRef PubMed PubMedCentral
    13.  
  13. Rumiantceva AV, Zhyhulyna VV. MMPs and their role in parodontytis development. Act Quest Human Natur Sci. 2014;(8):321-7. [Russian].
    14.  
  14. Hamed GM, Fattah MF. Clinical Relevance of matrix metalloproteinase 9 in patients with acute coronary syndrome. Clin Appl Thromb Hemost. 2015;21(8):705-11. CrossRef PubMed
    15.  
  15. Mahmoodi K, Kamali K, Karami E. et al. Plasma concentration, genetic variation, and gene expression levels of matrix metalloproteinase 9 in Iranian patients with coronary artery disease. J Res Med Sci.2017;22:8. CrossRef PubMed PubMedCentral
    16.  
  16. Shu J, Ren N, Du J-B, Zha M. Increased levels of interleukin-6 and matrix metalloproteinase-9 are of cardiac origin in acute coronary syndrome. Scand Cardiovasc J. 2007;41:149-54. CrossRef PubMed
    17.  
  17. Atkinson JJ, Lutey BA, Suzuki Y. et al. The role of matrix metalloproteinase-9 in cigarette smoke-induced emphysema. Am J Respir Crit Care Med. 2011;183(7):876-84. CrossRef PubMed PubMedCentral
    18.  
  18. Grzela K, Litwiniuk M, Zagorska W, Grzela T. Airway Remodeling in Chronic Obstructive Pulmonary Disease and Asthma: the Role of Matrix Metalloproteinase-9. Arch Immunol Ther Exp (Warsz). 2016;64:47-55. CrossRef PubMed PubMedCentral
    19.  
  19. Basanets AV, Dolinchuk LV, Andrushchenko TA. The association of promoter gene matrixmetalloproteinase-9 polymorphism C-1562->T with the risk of chronic obstructive pulmonary disease in miners. Fiziol Zh. 2014;60(6):16-21. [Ukrainian]. CrossRef  
  20. Ilumets Ilumets H, Rytilä PH, Sovijärvi AR. et al. Transient elevation of neutrophil proteinases in induced sputum during COPD exacerbation. Scand J Clin Lab Invest. 2008;68(7):618-23. CrossRef PubMed
    21.  
  21. Rogowicz A, Zozulinska D, Wierusz-Wysocka B. Role of matrics metalloproteinases in the development of vascular complications of diabetes mellitus - clinical implications. Pol Arch Med Wewn. 2007;117(3):43-8. PubMed
    22.  
  22. Ziablitsev SV, Korobova AV, Petrenko OV, Serduk VN, Mogilevsky SU. Role of matrix metalloproteinase 9 and its tissue inhibitor 1 in development and prognosis of diabetic retinopathy Fiziol Zh. 2016;62(5):37-44. [Ukrainian]. CrossRef  
  23. Wu Q-W, Yang Q-M, Huang Y-F et al. Expression and Clinical Significance of Matrix Metalloproteinase-9 in Lymphatic Invasiveness and Metastasis of Breast Cancer. PLoS ONE. 2004;9(5):97804. CrossRef PubMed PubMedCentral
    24.  
  24. Blankenberg S, Rupprecht HJ, Poirier O. et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003; 07:1579-85. CrossRef PubMed
    25.  
  25. Pecherina TV, Gruzdeva OV, Kashtalap VV, Barbarash OL. Role of MMPs in prognostic assessment in patients with STEMI myocardial infarction in hospital period. Cardiology. 2013;(6):18-24. [Russian]. PubMed
    26.  
  26. Fukuda D, Shimada K, Tanaka A. et al. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol. 2006;97(2):175-80. CrossRef PubMed
    27.  
  27. Lesnichenko IF, Gritcaev SV, Kapustin SI. MMP: characteristics and role during the leucogenesis and prognostic meanings. Quest Oncol. 2011;57(3):286-94 [Russian].
    28.  
  28. Liu P-Y. Genotype-Phenotype Association of Matrix Metalloproteinase-3 Polymorphism and Its Synergistic Effect With Smoking on the Occurrence of Acute Coronary Syndrome. Am J Cardiol. 2006;98:1012-7. CrossRef PubMed
    29.  
  29. Samnegard A, Silvera A, Lundman P. et al. Serum matrix metalloproteinase-3 concentration is influenced by MMP- 3 1612 5A/6A promoter genotype and associated with myocardial infarction. J Intern Med. 2005;258:411-9. CrossRef PubMed
    30.  
  30. Xu X, Wang L, Xu C, Zhang P. Variations in matrix metalloproteinase-1, -3, and -9 genes and the risk of acute coronary syndrome and coronary artery disease in the Chinese Han population. Coron Artery Dis. 2013;24(4):259-65. CrossRef PubMed
    31.  
  31. Wu TC, Leu HB, Lin WT. et al. Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease. Eur J Clin Invest. 2005;35(9):537-45. CrossRef PubMed
    32.  
  32. Gueders MM, Balbin M, Rocks N. et al. Matrix metalloproteinase-8 deficiency promotes granulocytic allergeninduced airway inflammation. J Immunol. 2005;175: 2589-97. CrossRef PubMed
    33.  
  33. Korpi JT, Astrom P, Lehtonen N. Healing of extraction sockets in collagenase-2 (matrix metalloproteinase-8)- deficient mice. Eur J Oral Sci. 2009;117:248-54. CrossRef PubMed
    34.  
  34. Kuula H, Salo T, Pirila E. et al. Local and systemic responses in matrix metalloproteinase 8-deficient mice during Porphyromonas gingivalis-induced periodontitis. Infect Immun. 2009;77:850-59. CrossRef PubMed PubMedCentral
    35.  
  35. Owen CA, Hu Z, Lopez-Otin C, Shapiro SD. Membranebound matrix metalloproteinase-8 on activated polymorphonuclear cells is a potent, tissue inhibitor of metalloproteinase-resistant collagenase and serpinase. J Immunol. 2004;172: 7791-803. CrossRef PubMed
    36.  
  36. Sorsa T, Tjaderhane L, Konttinen YT. Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann Med. 2006; 38:306-21. CrossRef PubMed
    37.  
  37. Sorsa T, Tjaderhane L, Salo T. Matrix metalloproteinases (MMPs) in oral diseases. Oral Dis. 2004;10:311-8. CrossRef PubMed
    38.  
  38. Herman MP, Sukhova GK, Libby P. et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation. 2001;104:1899-904. CrossRef PubMed
    39.  
  39. Kato R, Momiyama Y, Ohmori R. et al. Plasma matrix metalloproteinase-8 concentrations are associated with the presence and severity of coronary artery disease. Circ J. 2005;69:1035-40. CrossRef PubMed
    40.  
  40. Turu MM, Krupinski J, Montaner J. et al. Matrix metalloproteinases in plaque and plasma from patients with advanced carotid atherosclerosis. Atherosclerosis. 2006; 187:161-9. CrossRef PubMed
    41.  
  41. Momiyama Y, Ohmori R, Tanaka N. High plasma levels of matrix metalloproteinase-8 in patients with unstable angina. Atherosclerosis. 2010;209:206-10. CrossRef PubMed
    42.  
  42. Momiyama Y, Ohmori R, Tanaka N. et al. Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound. Atherosclerosis. 2006;187:161-9. CrossRef PubMed
    43.  
  43. Qiang H, Zhou ZX, Ma AQ. et al. Implications of serum matrix metalloproteinase-8 elevation in patients with acute coronary syndrome. Nan Fang Yi Ke Da Xue Xue Bao. 2007;27:831-3. PubMed
    44.  
  44. Tuomainen AM, Nyyssonen K, Laukkanen JA. et al. Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men. Arterioscler Thromb Vasc Biol. 2007;27:2722-8. CrossRef PubMed
    45.  
  45. Laxton RC, Hu Y, Duchene J. A role of matrix metalloproteinase-8 in atherosclerosis. Circ Res. 2009; 05 (9): 921-9. CrossRef PubMed PubMedCentral
    46.  
  46. Allal-Elasmi M, Zayani Y, Zidi W. et al. The measurement of circulating matrix metalloproteinase-8 and its tissue inhibitor and their association with inflammatory mediators in patients with acute coronary syndrome. Clin Lab. 2014; 60(6):951-6. CrossRef  
  47. Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): An ancient family with structural and functional diversity. Biochim Biophys Acta. 2010;1803 (1):55-71. CrossRef PubMed PubMedCentral
    48.  
  48. Opstad TB, Pettersen AA, Weiss TW. et al. Genetic variation, gene-expression and circulating levels of matrix metalloproteinase-9 in patients with stable coronary artery disease. Clin Chim Acta. 2012;413(1-2):113-20. CrossRef PubMed
    49.   Tepliakov AT, Berezikova EN, Shylov SN. Assessment of role of MMP-3 gen polymorphism in chronic heart failure development. Therapeutic Arch. 2015;87 (4):8-  
  49. [Russian].
    50.  
  50. Zhang B, Ye S, Herrmann SM. et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation. 1999;99:1788-94. CrossRef PubMed
    51.  
  51. Cho HJ, Chae IH, Park KW. et al. Functional polymorphism in the promoter region of the gelatinase B gene in relation to coronary artery disease and restenosis after percutaneous coronary intervention. J Hum Genet. 2002;47:88-91. CrossRef PubMed
    52.  
  52. Morgan AR, Zhang B, Tapper W. et al. Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease. J Mol Med (Berl). 2003;81:321-6. CrossRef PubMed
    53.  
  53. Alp E, Menevse S, Tulmac M. et al. Lack of association between matrix metalloproteinase-9 and endothelial nitric oxide synthase gene polymorphisms and coronary artery disease in Turkish population. DNA Cell Biol. 2009;28:343-50. CrossRef PubMed
    54.  
  54. Haberbosch W, Gardemann A. Gelatinase B C(-1562) T polymorphism in relation to ischaemic heart disease. Scand J Clin Lab Invest. 2005;65:513-22. CrossRef PubMed
    55.  
  55. Saedi M, Vaisi-Raygani A, Khaghani S. et al. Matrix metalloproteinase-9 functional promoter polymorphism 1562C>T increased risk of early-onset coronary artery disease. Mol Biol Rep. 2012;39(1):555-62. CrossRef PubMed
    56.  
  56. Morgan TM, Krumholz HM, Lifton RP, Spertus JA. Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA. 2007;297:1551-61. CrossRef PubMed
    57.  
  57. Fallah S, Seifi M, Ghasemi A, et. al. Matrix metalloproteinase-9 and paraoxonase 1 Q/R192 gene polymorphisms and the risk of coronary artery stenosis in Iranian subjects. J Clin Lab Anal. 2010;24:305-10. CrossRef PubMed
    58.  
  58. Wang L, Xu D, Wu X, et al. Polymorphisms of matrix metalloproteinases in myocardial infarction: a metaanalysis. Heart. 2011;97(19):1542-6. CrossRef PubMed
    59.  
  59. Setianto BY, Mubarika S, Irawan B, et al. Association Between High Serum Matrix Metalloproteinase-9 and MMP-9 (-1562C>T) Polymorphism in Patients With ST-Elevation Acute Myocardial Infarction. Cardiol Res. 2012;3(5):222-9. CrossRef  
  60. Zhang F-X, Sun D-P, Guan N, et al. Association Between −1562C>T Polymorphism in the Promoter Region of Matrix Metalloproteinase-9 and Coronary Artery Disease: A Meta-Analysis. Gen Test Molecul Biomarkers. 2014;18(2):98-105. CrossRef PubMed
    61.  
  61. Ye S, Watts GF, Mandalia S, et al. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J. 1995;73(3):209-15. CrossRef PubMed PubMedCentral
    62.  
  62. Beyzade S, Zhang S, Wong Y, et al. Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction. J Am Coll Cardiol. 2003;41(12):2130-37. CrossRef  
  63. Hirashiki A, Yamada Y, Murase Y, et al. Association of gene polymorphisms with coronary artery disease in low or high risk subjects defined by conventional risk factors. J Am Coll Cardiol. 2003;42:1429-37. CrossRef  
  64. Humphries SE, Martin S, Cooper J, Miller G. Interaction between smoking and the stromelysin-1 (MMP3) gene 5A/6A promoter polymorphism and risk of coronary heart disease in healthy men. Ann Hum Genet. 2002;66:343-52. CrossRef PubMed
    65.  
  65. Schwarz A, Haberbosch W, Tillmanns H, Gardemann A. The stromelysin 1 5A/6A promoter polymorphism is a disease marker for the extent of coronary heart disease. Dis Markers. 2002;18:121-8. CrossRef PubMed PubMedCentral
    66.  
  66. Abilleira S, Bevan S, Markus HS. The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis. J Med Genet. 2006;43:897-901. CrossRef PubMed PubMedCentral
    67.  
  67. Pollanen PJ, Lehtimaki T, Ilveskoski E, et al. Coronary artery calcification is related to functional polymorphism of matrix metalloproteinase 3: the Helsinki Sudden Death Study. Atherosclerosis. 2002;165:329-35. CrossRef  
  68. Yamada Y, Izawa H, Ichihara S, et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. New Engl J Med. 2002;347:1916-23. CrossRef PubMed
    69.  
  69. Liu PY, Chen JH, Li YH, et al. Synergistic effect of stromelysin-1 (matrix metallo-proteinase-3) promoter 5A/6A polymorphism with smoking on the onset of young acute myocardial infarction. Thromb Haemost. 2003;90:132-9. CrossRef PubMed
    70.  
  70. Gao B, Li ZC. Association between serum matrix metalloproteinase-3 concentration and the promoter 5A/6A polymorphism in patients with coronary heart disease. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2004;16:536-9. PubMed
    71.  
  71. Vanessa LN, Daiane N, Crislaine AP, et al. Matrix metalloproteinase gene polymorphisms in patients with coronary artery disease. Genet Mol Biol. 2007;30(3):505-10. CrossRef  
  72. Mazdorova EV, Riabikov AN, Maksymov VN et al. The relation between carotid atherosclerosis and 5A/6A polymorphism of MMP-3 gen. Siber Sci Med J. 2010;6(30):46-51. [Russian].
    73.  
  73. Beton O, Arslan S, Acar B, et al. Association between MMP-3 and MMP-9 polymorphisms and coronary artery disease. Biomed Rep. 2016;5:709-14. CrossRef PubMed PubMedCentral
    74.  
  74. Hoppmann P, Koch W, Schömig A, Kastrati A. The 5A/6A polymorphism of the stromelysin-1 gene and restenosis after percutaneous coronary interventions. Eur Heart J. 2004;25:335-41. CrossRef PubMed
    75.  
  75. Rauramaa R, Vaisanen SB, Luong LA, et al. Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol. 2000;20:2657-62. CrossRef PubMed
    76.  
  76. Terashima M, Akita H, Kanazawa K, et al. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation. 1999;99(21):2717-19. CrossRef PubMed
    77.  
  77. Pradhan-Palikhe P, Pussinen PJ, Vikatmaa P, et al. Single nucleotide polymorphism -799C/T in matrix metalloproteinase-8 promoter region in arterial disease. Innate Immun. 2012;18:511-7. CrossRef PubMed
    78.  
  78. Djurić T, Stanković A, Končar I, et al. Association of MMP-8 promoter gene polymorphisms with carotid atherosclerosis: preliminary study. Atherosclerosis. 2011;219(2):673-8. CrossRef PubMed
    79.  
  79. Yi Z, Yi H, Xue C, Zhi Z. Association between matrix metalloproteinase-8 -799C/T polymorphism and instability of carotid plaque. Ather Risk Comm. 2012;29(1):60-63.
    80.  
  80. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci. 2006;11:529-43. CrossRef PubMed
    81.  
  81. Kaylina AN, Ogorodova LM, Chasovskyh YuP, Kremer EE, 2013. The markers of MMPs system (MMP-2, MMP- 9, TIMP-1) in children with juvenile arthritis. Act Quest Ped. 2013;(7):36-40. [Russuian].
    82.  

© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2021.